Using a combination of small molecule inhibitors and genetic suppression of SHMT, we validated the combined repression of SHMT1 and SHMT2 as a candidate therapeutic approach for T-ALL. This evidence concerns the gene SHMT1 and acute lymphoblastic leukemia.